0001209191-23-010120.txt : 20230216 0001209191-23-010120.hdr.sgml : 20230216 20230216170015 ACCESSION NUMBER: 0001209191-23-010120 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230214 FILED AS OF DATE: 20230216 DATE AS OF CHANGE: 20230216 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ashe Andrew D. CENTRAL INDEX KEY: 0001573163 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40489 FILM NUMBER: 23639226 MAIL ADDRESS: STREET 1: C/O DYAX CORP. STREET 2: 55 NETWORK DRIVE CITY: BURLINGTON STATE: MA ZIP: 01803 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Verve Therapeutics, Inc. CENTRAL INDEX KEY: 0001840574 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 824800132 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 201 BROOKLINE AVENUE STREET 2: SUITE 601 CITY: BOSTON STATE: MA ZIP: 02215 BUSINESS PHONE: (978) 501-3026 MAIL ADDRESS: STREET 1: 201 BROOKLINE AVENUE STREET 2: SUITE 601 CITY: BOSTON STATE: MA ZIP: 02215 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-02-14 0 0001840574 Verve Therapeutics, Inc. VERV 0001573163 Ashe Andrew D. C/O VERVE THERAPEUTICS, INC. 201 BROOKLINE AVENUE, SUITE 601 BOSTON MA 02215 0 1 0 0 See Remarks Stock Option (right to buy) 21.76 2023-02-14 4 A 0 182800 0.00 A 2033-02-13 Common Stock 182800 182800 D The option was granted on February 14, 2023. 25% of the shares underlying the option will vest on February 14, 2024, and the remainder are scheduled to vest in equal monthly installments thereafter until February 14, 2027. President, Chief Operating Officer and General Counsel /s/ Andrew Ashe 2023-02-16